Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus *

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

• Publication date

  2008-03-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-2008-1058090PMID 18401832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• Alpha cell function in health and disease: influence of glucagon-like peptide-1

  2005cited by this paper
• Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance.

  2003cited by this paper
• Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness

  2003cited by this paper
• Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men

  1997cited by this paper
• Counterregulatory Hormone Responses to Hypoglycemia in the Elderly Patient with Diabetes

  1994cited by this paper

• Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis

  2023cites this paper
• Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis

  2022cites this paper
• Prescription of DPP4 inhibitors: indication and effect on glycosylated hemoglobin in a primary care institution of Colombia

  2022cites this paper
• Optimal Type 2 Diabetes Mellitus Management and Active Ageing

  2021cites this paper
• An Observational Study to Evaluate Effect of Vildagliptin in Combination with Metformin and Glimepiride on Glycaemic Control and lipid profile in T2DM Patients

  2021cites this paper
• A Single-Center, Observational, Retrospective Cost-Effective Analysis of Treating Inadequately Controlled Type 2 Diabetes Mellitus by Addition of DPP4 Inhibitors Versus Intensified Treatment with Conventional Drugs

  2021cites this paper
• Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan

  2020cites this paper
• Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

  2020cites this paper
• Clinical Use of DPP-4 Inhibitors

  2019cites this paper
• Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

  2018cites this paper
• Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.

  2018cites this paper
• Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing

  2017influential citation
• Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.

  2017cites this paper
• Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

  2016cites this paper
• Glycemic Reaction of Glimepiride Combined with Popular Egyptian Antidiabetic Drinks of Fenugreek and Coffee in Diabetic Rats

  2016cites this paper
• An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Role of Insulin Therapy In Diabetes.

  2016cites this paper
• Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England

  2016cites this paper
• Novel Therapeutic Approaches in Diabetes.

  2016cites this paper
• Role of Sitagliptin-Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes Mellitus-An Overview

  2015cites this paper
• Pharmaceutical Equivalent study of Vildagliptin Formulation

  2015cites this paper
• Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?

  2015cites this paper
• Secretion of glucagon-like peptide-1 ( GLP-1 ) in type 2 diabetic patients : Study of its relation to glucose lowering effect of dipeptidyl peptidase IV ( DPP-IV ) inhibitors

  2015cites this paper
• Hot Topics in Primary Care: Management of Opioid-induced Constipation.

  2015cites this paper
• Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

  2015influential citation
• Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.

  2015cites this paper
• Drug Evaluation Vildagliptin , a dipeptidyl peptidase-4 inhibitor , for the treatment of type 2 diabetes

  2014cites this paper
• Insuline gecombineerd met een DPP-4-remmer: een nieuwe behandeloptie bij type 2 diabetes mellitus

  2014cites this paper
• Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

  2014cites this paper
• Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment

  2014cites this paper
• Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

  2014cites this paper
• DPP-4 inhibitors: pharmacological differences and their clinical implications

  2014cites this paper
• Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review

  2014cites this paper
• Efficacy of Adding Once-Daily Insulin Glulisine in Japanese Type 2 Diabetes Patients Treated with Insulin Glargine and Sitagliptin

  2014cites this paper
• Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin

  2014influential citation
• Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

  2013cites this paper
• Sitagliptin and Vildagliptin Efficacy on Carbohydrate and Lipid Metabolism in Elderly Patients with Type 2 Diabetes

  2013cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Preservation of Pancreatic Islet-Cell Function : A Critical Appraisal of the Evidence ChaPTeR 5

  2013cites this paper
• Combining Incretin-Based Therapies With Insulin

  2013cites this paper
• Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

  2013cites this paper
• Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes

  2013cites this paper
• Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy

  2013cites this paper
• Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.

  2013cites this paper
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

  2013cites this paper
• Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?

  2013cites this paper
• The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes.

  2013cites this paper
• Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin

  2013cites this paper
• The incretin hormones: from scientific discovery to practical therapeutics

  2012cites this paper
• Glimepiride: evidence-based facts, trends, and observations

  2012cites this paper
• Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality

  2012cites this paper
• Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

  2012cites this paper
• Non-Insulin Agents for Diabetes

  2012cites this paper
• Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.

  2012cites this paper
• One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

  2012cites this paper
• Vildagliptin

  2012cites this paper
• Vildagliptin

  2012cites this paper
• Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence

  2012cites this paper
• Type 2 Diabetes: Uses of thiazolidinediones and insulin

  2011cites this paper
• Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

  2011cites this paper
• Emerging role of insulin with incretin therapies for management of type 2 diabetes

  2011cites this paper
• Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

  2011cites this paper
• Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients

  2011cites this paper
• Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

  2011cites this paper
• Type 2 Diabetes

  2011cites this paper
• Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans

  2011influential citation
• Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

  2011cites this paper
• GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

  2011cites this paper
• Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

  2011cites this paper
• Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

  2010cites this paper
• Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

  2010cites this paper
• Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

  2010cites this paper
• weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

  2010cites this paper
• How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies

  2010cites this paper
• Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  2010cites this paper
• Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

  2010cites this paper
• Role of vildagliptin in managing type 2 diabetes mellitus in the elderly

  2010cites this paper
• The Continuation of Oral Medications with the Initiation of Insulin Therapy in Type 2 Diabetes: A Review of the Evidence

  2010cites this paper
• Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population

  2010cites this paper
• An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

  2010cites this paper
• The evolving place of incretin-based therapies in type 2 diabetes

  2010cites this paper
• Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study

  2010cites this paper
• The Future of Diabetes Therapy

  2010cites this paper
• Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

  2010cites this paper
• New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes

  2009cites this paper
• Vildagliptin in clinical practice: a review of literature

  2009cites this paper
• DPP-4 Inhibitors in Clinical Practice

  2009cites this paper
• Association gliptines et sulfamides hypoglycémiants

  2008cites this paper
• Vildagliptin: a new oral treatment for type 2 diabetes mellitus

  2008cites this paper
• [Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes].

  2008cites this paper
• Hormony inkretynowe w leczeniu cukrzycy typu 2. Część II. Inkretyny — nowe możliwości farmakoterapii cukrzycy typu 2 Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins — new possibilities for pharmacotherapy of type 2 diabetes

  2008cites this paper
• Dipeptidyl Peptidase-4 Inhibition— Advances in our Understanding of Diabetes Management

  2008cites this paper
• Not for Sale or Commercial Distribution

  2007cites this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper
• Vascular Health and Risk Management Dovepress Assessing the General Safety and Tolerability of Vildagliptin: Value of Pooled Analyses from a Large Safety Database versus Evaluation of Individual Studies

  year unknowncites this paper
• Vascular Health and Risk Management Dovepress Weight Neutrality with the Dpp-4 Inhibitor, Vildagliptin: Mechanistic Basis and Clinical Experience

  year unknowncites this paper